Atea Pharmaceuticals is a startup based in the United States, most recent round Series-c-plus, 1 tracked investor.
Atea Pharmaceuticals is a company headquartered in the United States. Its most recent tracked round is Series-c-plus. Brouky records 1 investor associated with the company.
Atea Pharmaceuticals is a clinical-stage biopharmaceutical company developing and commercializing antiviral therapies for life‑threatening viral diseases. The company went public in October 2020 (NASDAQ: AVIR) and entered an exclusive ex‑US partnership with Roche.
Funding rounds, investor list, risk signals, and comparable startups, all gated to subscribers.